Search results
Jun 28, 2024 · Daiichi Sankyo is a company that discovers, develops and delivers new medicines for various cancers and other diseases. Learn about its stories, news, initiatives, pipeline, governance and sustainability.
- Products
Products - Daiichi Sankyo
- Investors
Investors - Daiichi Sankyo
- About Us
Daiichi Sankyo is a global pharmaceutical company with...
- Pipeline
Pipeline - Daiichi Sankyo
- Research & Development
Research & Development - Daiichi Sankyo
- IR News
IR News - Daiichi Sankyo
- Media
Media - Daiichi Sankyo
- Our Stories
Our Stories - Daiichi Sankyo
- Products
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan.
Daiichi Sankyo provides innovative products and services in 29 countries/regions around the world. Learn about its mission, vision, values, strengths, R&D capabilities, and history as a pharma innovator.
Daiichi Sankyo is a Japanese pharmaceutical company with a global presence and a mission to improve quality of life for patients. Learn about its culture, values, opportunities and locations for employees.
For people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges.
Jun 26, 2024 · Daiichi Sankyo and Merck entered into a global collaboration in October 2023 to jointly develop and commercialize patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd), except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and ...
Jun 28, 2024 · An antibody-drug conjugate patent arbitration fight that Seagen waged against Daiichi Sankyo has officially ended in a win for the Japanese company. Rather than getting any compensation from its ...
